Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXT3003 in Charcot-Marie-Tooth Disease Type 1A
NCT02579759Phase 3Completed
- Sponsor
- Pharnext
- Start
- Dec 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of PXT 3003 in Charcot-Marie-Tooth disease type 1A (CMT1A), sponsored by Pharnext. Started Dec 2015; status: completed.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NCT02579759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579759.